CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Traditional Chinese Medicine PrescriptionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug990 no interventional study Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D003920 Diabetes Mellitus, NIH 0.58
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19

In December 2019, a new type of pneumonia, COVID-2019 outbroke in Wuhan ,China, and currently the infected has been reported in more than at least 75 countries. Patients with severe COVID-19 have rapid disease progression and high mortality rate. This may attribute to the excessive immune response caused by cytokine storm. Strategies based on anti-virus drugs and treatments against symptoms have now been employed. However, these managements can't effectively treat the lethal lung injury and uncontrolled immune responses, especially in the elderly with severe COVID-19. Traditional Chinese Medicine (TCM), which treats the disease from anther perspective, has achieved satisfactory results. National Health Commission of China released a series of policies to enhance the administration of TCM prescriptions. This study is aimed to evaluate the efficacy and safety of Traditional Chinese Medicine as an adjuvant treatment for severe COVID-19.

NCT04323332 COVID-19 Drug: Traditional Chinese Medicine Prescription

Primary Outcomes

Measure: Length of hospital stay (days)

Time: First treatment date up to 3 months

Secondary Outcomes

Measure: Duration (days) of supplemental oxygenation

Time: First treatment date up to 3 months

Measure: CT imaging changes

Time: First treatment date up to 3 months

Measure: Mortality rate

Time: First treatment date up to 3 months

Measure: Time to Clinical Improvement (TTCI)

Time: First treatment date up to 3 months

Description: The pneumonia severity index is a clinical tool helping in the risk stratification of patients with community-acquired pneumonia. It ranges from 0-395 scores and a higher score indicates higher death risk.

Measure: The pneumonia severity index scores

Time: First treatment date up to 3 months

Measure: Time to COVID-19 nucleic acid testing negativity in throat swab

Time: First treatment date up to 3 months

Description: Changes in leukocyte, neutral, lymphocyte counts and absolute lymphocyte count from baseline

Measure: Blood immune cell count

Time: Baseline, 7 and/ or 14 days

Description: Changes in blood interleukin-6, c-reactive protein,SS-A/Ro antibodies and serum ferritin from baseline.

Measure: Serum inflammatory markers

Time: Baseline, 7 and/ or 14 days

Description: Changes in erythrocyte sedimentation rate from baseline.

Measure: Erythrocyte sedimentation rate

Time: Baseline, 7 and/ or 14 days

Description: Changes in platelets and D-dimers from baseline.

Measure: Platelet and D-dimer changes

Time: Baseline, 7 and/ or 14 days

Description: Changes in serum creatinine from baseline.

Measure: Creatinine changes

Time: Baseline, 7 and/ or 14 days

Description: Changes in serum muscle enzymes from baseline, including alanine aminotransferase , AST, creatine kinase, LDH.

Measure: Muscle enzymes changes

Time: Baseline, 7 and/ or 14 days

Description: Dosing time and amounts of antibiotics；the categories of the antibiotics

Measure: Usage of antibiotics

Time: First treatment date up to 3 months

Description: Dosing time and amounts of glucocorticoids

Measure: Usage of glucocorticoids

Time: First treatment date up to 3 months

Measure: Frequency of adverse events

Time: First treatment date up to 3 months

No related HPO nodes (Using clinical trials)